I will support legislation that codifies Most Favored Nation prescription drug pricing agreements and enforces lower Medicare drug prices if manufacturers do not agree by a set deadline.

Daniel Meuser · Pennsylvania · Republican

policy impact 4.00 specificity 5.00 extraction confidence 99%

Contest this claim

Occurrences

This bill incentivizes drug manufacturers to negotiate Most Favored Nation (MFN) pricing agreements with the Trump Administration. Manufacturers that decline to agree by December 2028 would be required to provide Medicare MFN pricing for five years.

The bill creates an enforcement mechanism to secure MFN pricing agreements and require Medicare MFN pricing if manufacturers refuse.

Meuser Introduces Bill to Lower Prescription Drug Prices | Representative Dan Meuser
primary · press_release · model gpt-5.4-mini

To amend title XI of the Social Security Act to require the Center for Medicare and Medicaid Innovation to test a model implementing most-favored-nation drug pricing.

Meuser introduced legislation requiring CMS Innovation to test a most-favored-nation drug pricing model beginning in 2029 unless manufacturers enter agreements first.

meuspa_041_xml.pdf
primary · other · model gpt-5.4-mini

Evidence

Meuser said he introduced the Most Favored Patient Act to lower prescription drug costs, codify existing Most Favored Nation deals, and require Medicare MFN pricing for five years if manufacturers did not agree by Dec. 31, 2028.

He publicly backed and introduced the exact kind of MFN legislation described in the pledge.

delivered same_term A for effort

Meuser Introduces Bill to Lower Prescription Drug Prices | Representative Dan Meuser
primary · model gpt-5.4-mini · confidence 98%

Contest this evidence item

The bill text amends the Social Security Act to require CMMI to test a Most Favored Nations Pricing Model beginning Jan. 1, 2029; it sets a covered-agreement deadline of Dec. 31, 2028 and applies Medicare MFN pricing to holdouts.

The statutory text matches the promise: codify MFN pricing, set a deadline, and impose lower Medicare pricing if manufacturers do not agree.

delivered same_term A for effort

meuspa_041_xml.pdf
primary · model gpt-5.4-mini · confidence 99%

Contest this evidence item

Assessments

delivered same_term A for effort

The promise was to support legislation with specific Most Favored Nation drug-pricing terms, not necessarily to enact it into law. Evidence shows Meuser introduced the Most Favored Patient Act in March 2026, and the bill text matches the pledge by codifying MFN-style pricing arrangements, setting a manufacturer agreement deadline of December 31, 2028, and imposing lower Medicare MFN pricing on holdouts. For a federal House member, introducing and backing the exact legislation promised is sufficient to count as delivery of a support-legislation pledge.

provider codex_cli · model gpt-5.4 · confidence 97%